SINGAPORE – 03 March 2025 – Tikva Allocell is pleased to announce that its CEO and Founder, Ivan Horak, will be a featured speaker at the 3rd Clinical Trial Festival Asia 2025, organized by IMAPAC. The event will be held from 12th to 13th March 2025 in Marina Bay Sands Expo and Convention Center, Singapore.
The Clinical Trial Festival Asia is a premier event that brings together leading professionals from the pharmaceutical, biotechnology, and clinical research sectors. This conference provides a platform for industry experts to discuss the latest trends, challenges, and advancements in clinical trial management, technology, and patient engagement. The 3rd edition of this festival aims to foster collaboration and drive innovation in the Asia-Pacific region’s clinical research landscape.
Ivan Horak will be presenting on “An Industry Perspective of Drug Development in Emerging Countries”, addressing the latest developments in cell therapy applications within clinical trials and the strategic approaches Tikva Allocell is implementing to enhance patient outcomes. His presentation will offer valuable insights into Tikva Allocell’s innovative contributions to the field and its commitment to advancing clinical research.
Tikva Allocell is dedicated to pioneering advancements in allogeneic cell therapy and is committed to driving meaningful progress in patient care through innovative clinical research.
Attendees are invited to attend Ivan Horak’s presentation and speak to company representatives to learn more about the company’s exciting work.
Jinkai TEO, MSc
Principal Data Scientist
Jinkai brings more than 10 years of experience in the pharmaceutical industry spanning from the bench as a translational scientist at Merck Sharp & Dohme (MSD) and managing analytics on CMC related activities (analytical development, DoE and QoD) at Tessa Therapeutics.
About Tikva Allocell
Tikva Allocell Pte Ltd is a late preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing highly specific second-generation allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV)-positive healthy individuals. Our approach exploits the intrinsic properties of Virus-Specific T cells (VSTs), enhanced by IP-protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.
For more information on Tikva, please visit www.tikvaallocell.com.
Investors and Media Contact
